Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2021-04-15 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
安信证券股份有限公司关于奥锐特药业股份有限公司2020年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年度现场检查报告" (2020 Annual On-site Inspection Report) by the sponsor (安信证券股份有限公司) regarding 奥锐特药业股份有限公司. It details the sponsor's on-site inspection activities during the continuous supervision period after the company's IPO, including governance, internal controls, information disclosure, use of raised funds, related party transactions, and operational status. The document is a detailed inspection report by the sponsor, not a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on the sponsor's inspection findings. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone inspection report related to regulatory compliance and internal controls, distinct from the full Annual Report (10-K). The document length (2638 characters) is relatively short but contains detailed inspection content, not just an announcement or certification. Therefore, the classification is AR with high confidence. FY 2020
2021-04-15 Chinese
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's use of idle raised funds for cash management through purchasing structured deposit products. It includes specifics about the entrusted financial institution, amounts, terms, risk control, and impact on the company. It references prior approvals by the board and shareholders, and provides financial data and risk disclosures. The document is not a full financial report like an Annual or Interim Report, nor is it a simple announcement of a report publication. It is a regulatory announcement about capital management activities related to fundraising proceeds. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length and detail support this classification with high confidence.
2021-04-13 Chinese
关于公司购买土地使用权的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's purchase of land use rights, detailing the transaction price, land location, contract terms, and potential risks. It is a specific corporate announcement about a capital asset acquisition and does not contain financial statements, audit information, or regulatory certifications. The document is relatively short (1787 characters) and focuses on a financing-related transaction (purchase of land use rights) rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-01-11 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 奥锐特药业股份有限公司 regarding the progress of using part of idle raised funds for cash management through entrusted financial products. It includes specifics about the entrusted financial product, the amount, the purpose, risk control, and the impact on the company. It references prior approvals by the board and shareholders, and provides financial data to support the announcement. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is a regulatory announcement about the company's capital management activities, specifically the use of idle raised funds for cash management. This fits best under Capital/Financing Update (CAP). The document length (5749 characters) and detailed content support this classification with high confidence.
2021-01-10 Chinese
关于拟购买土地使用权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding its intention to purchase land use rights. It details the transaction overview, voting results from the board meeting, risk factors, and the impact on the company. The document is relatively short (1717 characters) and focuses on a specific transaction rather than providing financial statements or comprehensive financial data. It is not a financial report, earnings release, or management discussion. It is an announcement about a capital expenditure transaction (land purchase) and related board approval. This fits best under Capital/Financing Update (CAP) as it relates to company financing activities and capital use. There is no indication it is a full report or regulatory filing of another type, nor is it a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2020-12-21 Chinese
第二届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.). It details the convening of the second board's fourth meeting, the voting results on specific proposals including land use rights purchase and internal share transfer between subsidiaries. The document includes meeting procedural compliance statements and voting outcomes. There is no financial data, no mention of annual or quarterly reports, no audit information, no earnings release, and no investor presentation. The content is focused on board decisions and changes in company structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a substantive announcement of board resolutions.
2020-12-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.